



Bianca Jean LaCaille

Associate

bianca.lacaille@dlapiper.com

Seattle

T: +1 206 839 4818

F: +1 206 494 1787

Bianca LaCaille's practice focuses on SEC reporting and capital markets transactions. Bianca handles IPOs and follow-on offerings, all aspects of corporate governance matters, SEC periodic and current reporting and stock exchange listing requirements and compliance.

Bianca has practiced in a variety of industries, including technology, healthcare, life sciences, biotechnology and retail.

CREDENTIALS

Admissions

- Washington

Prior Experience

Previously, Bianca worked as a Summer Associate at DLA Piper.

During law school, Bianca participated in the UW Law Entrepreneurial Law Clinic, where she helped technology entrepreneurs and small business owners with a range of early-stage corporate matters. She was also a legal intern at several large, Seattle-based technology companies.

Education

- J.D., University of Washington School of Law
Chief Online Editor *Washington Law Review*
- B.A., Psychology and English, University of Washington
cum laude
Phi Beta Kappa

RELATED SERVICES

- Corporate
- Mergers and Acquisitions
- Emerging Growth and Venture Capital
- Global Investment Funds
- Capital Markets

RELATED SECTORS

- Life Sciences
- Technology

Memberships

- Member, Washington State Bar Association
- Member, American Bar Association

NEWS

DLA Piper advises Cowen and Company, William Blair & Company, BTIG and Stephens Inc. as underwriters of Alpha Teknova IPO

12 July 2021

DLA Piper represented Cowen and Company, LLC, William Blair & Company, L.L.C., BTIG, LLC and Stephens Inc. as underwriters in the US\$110.4 million initial public offering of Alpha Teknova, Inc.

DLA Piper advises Akoya Biosciences in its US\$151 million initial public offering

3 May 2021

DLA Piper represented Akoya Biosciences, Inc. (Nasdaq: AKYA) in its recent initial public offering of 7,567,000 shares of its common stock at a price of \$20 per share, including the exercise of the underwriters' option to purchase 987,000 shares of common stock, less underwriting discounts and commissions.

DLA Piper advises Piper Sandler & Co. as sole book-running manager in connection with US\$92 million common stock offering by Infinity Pharmaceuticals

2 March 2021

DLA Piper represented Piper Sandler & Co. as sole book-running manager in connection with the US\$92 million public offering of common stock of Infinity Pharmaceuticals, a clinical-stage biotechnology company.

DLA Piper advises ON24 in its US\$428 million IPO

3 February 2021

DLA Piper represented ON24 Inc. (NYSE: ONTF) in its initial public offering of 8,560,930 shares of common stock at a price to the public of \$50 per share.
